Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 5 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| LISATA THERAPEUTICS, INC. | 209,753 | reported | 10 Jan 2022 | tx 4+209,753 |
| NewAmsterdam Pharma Co N.V. | 174,144 | reported | 02 Mar 2026 | tx 30+3,146,715−1,577,234 |
| Silence Therapeutics plc | 48,000 | reported | 02 Jan 2025 | tx 1+48,000 |
| TENAX THERAPEUTICS, INC. | 30,000 | reported | 09 Jan 2026 | tx 10+808,250−512 |
| BioAge Labs, Inc. | 22,000 | reported | 05 Jun 2025 | tx 3+70,986 |
| Omthera Pharmaceuticals, Inc. | 0 | reported | 18 Jul 2013 | tx 4+51,960−1,557,843 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 02 Mar 2026 | SALE | NewAmsterdam Pharma Co N.V. | 443,707 | 33.25 USD | |
| 02 Mar 2026 | EXERCISE | NewAmsterdam Pharma Co N.V. | 443,707 | — | |
| 02 Mar 2026 | EXERCISE | NewAmsterdam Pharma Co N.V. | 443,707 | 0.00 USD | deriv |
| 24 Feb 2026 | EXERCISE | NewAmsterdam Pharma Co N.V. | 64,708 | — | |
| 24 Feb 2026 | SALE | NewAmsterdam Pharma Co N.V. | 61,547 | 36.13 USD | |
| 24 Feb 2026 | SALE | NewAmsterdam Pharma Co N.V. | 3,161 | 36.46 USD | |
| 25 Feb 2026 | EXERCISE | NewAmsterdam Pharma Co N.V. | 58,253 | — | |
| 25 Feb 2026 | SALE | NewAmsterdam Pharma Co N.V. | 46,517 | 35.11 USD | |
| 25 Feb 2026 | SALE | NewAmsterdam Pharma Co N.V. | 10,436 | 35.96 USD | |
| 25 Feb 2026 | SALE | NewAmsterdam Pharma Co N.V. | 1,300 | 36.68 USD | |
| 26 Feb 2026 | EXERCISE | NewAmsterdam Pharma Co N.V. | 183,332 | — | |
| 26 Feb 2026 | SALE | NewAmsterdam Pharma Co N.V. | 165,408 | 33.63 USD | |
| 26 Feb 2026 | SALE | NewAmsterdam Pharma Co N.V. | 17,924 | 34.44 USD | |
| 26 Feb 2026 | EXERCISE | NewAmsterdam Pharma Co N.V. | 183,332 | 0.00 USD | deriv |
| 24 Feb 2026 | EXERCISE | NewAmsterdam Pharma Co N.V. | 64,708 | 0.00 USD | deriv |
| 25 Feb 2026 | EXERCISE | NewAmsterdam Pharma Co N.V. | 58,253 | 0.00 USD | deriv |
| 09 Jan 2026 | GRANT_AWARD | TENAX THERAPEUTICS, INC. | 30,000 | 0.00 USD | deriv |
| 07 Jan 2026 | GRANT_AWARD | NewAmsterdam Pharma Co N.V. | 81,000 | — | |
| 07 Jan 2026 | SALE | NewAmsterdam Pharma Co N.V. | 11,582 | — | |
| 07 Jan 2026 | GRANT_AWARD | NewAmsterdam Pharma Co N.V. | 364,000 | 0.00 USD | deriv |
| 01 Jul 2025 | GRANT_AWARD | TENAX THERAPEUTICS, INC. | 80,000 | 0.00 USD | deriv |
| 05 Jun 2025 | GRANT_AWARD | BioAge Labs, Inc. | 22,000 | 0.00 USD | deriv |
| 26 Mar 2025 | EXERCISE | NewAmsterdam Pharma Co N.V. | 38,394 | 0.00 USD | |
| 26 Mar 2025 | SALE | NewAmsterdam Pharma Co N.V. | 12,258 | — | |
| 26 Mar 2025 | GRANT_AWARD | NewAmsterdam Pharma Co N.V. | 30,992 | 0.00 USD |
1 purchase reported after at least 12 months of silence — most recent on 20 Jun 2024.